Efficacy of a moxidectin/imidacloprid spot-on formulation (Advocate®) for the treatment of Troglostrongylus brevior in naturally infected cats in a field study in Greece

Table 1 Pre- and post-treatment larval faecal shedding of cats included in the study to evaluate the efficacy of Advocate® in the treatment of natural troglostrongylosis

Study day	Group	n	Mean LPG	SD	SE	95% CI	Min-Max	ANOVA
0	G1	8	31.88	36.247	12.815	1.57–62.18	15–120	F = 0.468; P = 0.505
0	G2	8	46.88	50.351	17.802	4.78–88.97	15–165	F = 0.468; P = 0.505
28	G1	8	20.63	7.763	2.745	14.13–27.12	15–30	F = 56.467; P < 0.001*
28	G2	8	0	0	0	0	0	F = 56.467; P < 0.001*
56	G1	8	18.75	6.944	2.455	12.94–24.56	15–30	F = 58.333; P < 0.001*
56	G2	8	0	0	0	0	0	F = 58.333; P < 0.001*

Abbreviations: G1, cats treated with Advocate on study days 56/57 and 83/84; G2, cats treated with Advocate on study days 0 and 28/29; n, number of animals included in G1 or G2; LPG, larvae per gram; CI, confidence interval; SD, standard deviation; SE, standard error; Min, minimum; Max, maximum
*Statistically significant results

ISSN: 1756-3305